Figure 3.

lncRNA UCA1 Promotes Cisplatin Resistance In Vivo

(A) Photographs of tumors that developed in xenograft transplanted nude mouse tumor models treated orally with once daily cisplatin or NS as control for 4 weeks in different groups. The group settings were as follows: group 1, Lv-UCA1-transfected cells + cisplatin; group 2, Lv-UCA1-transfected cells + NS; group 3, Lv-NC-transfected cells + cisplatin; and group 4, Lv-NC-transfected cells + NS. (B) Weights of tumors that developed in xenografts from different groups. **p < 0.01 compared to respective groups. (C) IHC analysis of expression levels of Ki-67 in xenografts from different groups. (D) The percentage of Ki-67-positive cells in xenografts from different groups. All tests were performed at least three times. Data were expressed as mean ± SD. **p < 0.01.